X4 Pharmaceuticals (NASDAQ:XFOR) President Sells 24,576 Shares of Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) President John Volpone sold 24,576 shares of X4 Pharmaceuticals stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total transaction of $109,117.44. Following the completion of the transaction, the president directly owned 265,305 shares in the company, valued at $1,177,954.20. The trade was a 8.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

X4 Pharmaceuticals Stock Performance

XFOR stock remained flat at $4.29 on Thursday. 1,126,769 shares of the company traded hands, compared to its average volume of 562,019. The stock has a market capitalization of $425.35 million, a PE ratio of -3.57 and a beta of 0.37. The firm’s 50-day simple moving average is $4.04 and its 200 day simple moving average is $3.96. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45. X4 Pharmaceuticals, Inc. has a 1 year low of $2.45 and a 1 year high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. The company had revenue of $8.81 million for the quarter, compared to the consensus estimate of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 64.95%. As a group, equities analysts forecast that X4 Pharmaceuticals, Inc. will post -0.71 EPS for the current fiscal year.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of large investors have recently bought and sold shares of XFOR. Pettinga Financial Advisors LLC acquired a new stake in shares of X4 Pharmaceuticals in the 2nd quarter worth $47,000. Indivisible Partners purchased a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at about $40,000. SummitTX Capital L.P. acquired a new position in shares of X4 Pharmaceuticals during the first quarter worth about $46,000. Squarepoint Ops LLC purchased a new stake in X4 Pharmaceuticals in the 4th quarter valued at approximately $50,000. Finally, Two Sigma Investments LP acquired a new position in X4 Pharmaceuticals during the 3rd quarter worth approximately $47,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Analyst Upgrades and Downgrades

XFOR has been the topic of a number of research reports. Weiss Ratings lowered X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Leerink Partners initiated coverage on X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Finally, Wells Fargo & Company started coverage on X4 Pharmaceuticals in a research report on Friday, July 10th. They set an “overweight” rating and a $11.00 price objective for the company. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $11.25.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.